Literature DB >> 12055988

Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion.

Liselle Douyon1, David E Schteingart.   

Abstract

Obesity and starvation have opposing affects on normal physiology and are associated with adaptive changes in hormone secretion. The effects of obesity and starvation on thyroid hormone, GH, and cortisol secretion are summarized in Table 1. Although hypothyroidism is associated with some weight gain, surveys of obese individuals show that less than 10% are hypothyroid. Discrepancies have been reported in some studies, but in untreated obesity, total and free T4, total and free T3, TSH levels, and the TSH response to TRH are normal. Some reports suggest an increase in total T3 and decrease in rT3 induced by overfeeding. Treatment of obesity with hypocaloric diets causes changes in thyroid function that resemble sick euthyroid syndrome. Changes consist of a decrease in total T4 and total and free T3 with a corresponding increase in rT3. untreated obesity is also associated with low GH levels; however, levels of IGF-1 are normal. GH-binding protein levels are increased and the GH response to GHRH is decreased. These changes are reversed by drastic weight reduction. Cortisol levels are abnormal in people with abdominal obesity who exhibit an increase in urinary free cortisol but exhibit normal or decreased serum cortisol and normal ACTH levels. These changes are explained by an increase in cortisol clearance. There is also an increased response to CRH. Treatment of obesity with very low calorie diets causes a decrease in serum cortisol explained by a decrease in cortisol-binding proteins. The increase in cortisol secretion seen in patients with abdominal obesity may contribute to the metabolic syndrome (insulin resistance, glucose intolerance, dyslipidemia, and hypertension). States of chronic starvation such as seen in anorexia nervosa are also associated with changes in thyroid hormone, GH, and cortisol secretion. There is a decrease in total and free T4 and T3, and an increase in rT3 similar to findings in sick euthyroid syndrome. The TSH response to TRH is diminished and, in severe cases, thyroid-binding protein levels are decreased. In regards to GH, there is an increase in GH secretion with a decrease in IGF-1 levels. GH responses to GHRH are increased. The [table: see text] changes in cortisol secretion in patients with anorexia nervosa resemble depression. They present with increased urinary free cortisol and serum cortisol levels but without changes in ACTH levels. In contrast to the findings observed in obesity, the ACTH response to CRH is suppressed, suggesting an increased secretion of CRH. The endocrine changes observed in obesity and starvation may complicate the diagnosis of primary endocrine diseases. The increase in cortisol secretion in obesity needs to be distinguished from Cushing's syndrome, the decrease in thyroid hormone levels in anorexia nervosa needs to be distinguished from secondary hypothyroidism, and the increase in cortisol secretion observed in anorexia nervosa requires a differential diagnosis with primary depressive disorder.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12055988     DOI: 10.1016/s0889-8529(01)00023-8

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  49 in total

Review 1.  Enzymatic intracrine regulation of white adipose tissue.

Authors:  David DiSilvestro; Jennifer Petrosino; Ayat Aldoori; Emiliano Melgar-Bermudez; Alexandra Wells; Ouliana Ziouzenkova
Journal:  Horm Mol Biol Clin Investig       Date:  2014-07

Review 2.  Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy.

Authors:  Thomas W Buford; Stephen D Anton; Andrew R Judge; Emanuele Marzetti; Stephanie E Wohlgemuth; Christy S Carter; Christiaan Leeuwenburgh; Marco Pahor; Todd M Manini
Journal:  Ageing Res Rev       Date:  2010-05-14       Impact factor: 10.895

3.  Development of acromegaly in a patient with anorexia nervosa: pathogenetic and diagnostic implications.

Authors:  E de Menis; M Gola; A Giustina
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

4.  Relationship of thyroid function with body mass index and insulin-resistance in euthyroid obese subjects.

Authors:  B Ambrosi; B Masserini; L Iorio; A Delnevo; A E Malavazos; L Morricone; L F Sburlati; E Orsi
Journal:  J Endocrinol Invest       Date:  2010-03-25       Impact factor: 4.256

Review 5.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

6.  Fetal exposure to excess glucocorticoid is unlikely to explain the effects of periconceptional undernutrition in sheep.

Authors:  A L Jaquiery; M H Oliver; F H Bloomfield; K L Connor; J R G Challis; J E Harding
Journal:  J Physiol       Date:  2006-02-09       Impact factor: 5.182

7.  Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy.

Authors:  M Luisa Isidro; Manuel A Penín; Rosa Nemiña; Fernando Cordido
Journal:  Endocrine       Date:  2007-10-02       Impact factor: 3.633

8.  THE ENDOCRINOPATHIES OF MALE ANOREXIA NERVOSA: CASE SERIES.

Authors:  Aren Skolnick; Rifka C Schulman; Rodolfo J Galindo; Jeffrey I Mechanick
Journal:  AACE Clin Case Rep       Date:  2016

9.  Triiodothyronine (T3) and metabolic rate in adolescents with eating disorders: Is there a correlation?

Authors:  D L Aschettino-Manevitz; R M Ornstein; W Meyer Sterling; N Kohn; M Fisher
Journal:  Eat Weight Disord       Date:  2012-11-26       Impact factor: 4.652

10.  Raised serum TSH in morbid-obese and non-obese patients: effect on the circulating lipid profile.

Authors:  Mario Rotondi; Paola Leporati; Maria Ileana Rizza; Alessandra Clerici; Gloria Groppelli; Cristina Pallavicini; Antonella La Manna; Rodolfo Fonte; Flavia Magri; Bernadette Biondi; Luca Chiovato
Journal:  Endocrine       Date:  2013-03-23       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.